24Jul 2022
Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine - A Prospective Observational Study

Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine - A Prospective Observational Study

Since the introduction of various vaccines against SARS-CoV-2 at the end of 2020, infection rates have continued to climb worldwide. This led to establishment of a third dose vaccination in several countries, known as a booster. To date, there has been little real-world data about the immunological effect of this strategy. The study included 243 healthcare workers who provided blood samples and questionnaires pre- and post- third vaccination. This study detected a BMI-dependent antibody increase after the third dose of BNT162b2 following different vaccination protocols. In addition, all participants showed a significant increase in their immune response. This, in combination with the low rate of post-vaccination symptoms, underlines the potential beneficial effect of a BNT162b2-booster dose.

  • #family health

Like

Save

Share